TOP HEADLINES

Featured Story

Glaxo's malaria vaccine gets EMA green light

GlaxoSmithKline's malaria vaccine, RTS,S or Mosquirix, has won a positive opinion from the EMA's Committee for Medicinal Products for Human Use for use in children aged 6 weeks to 17 months outside the European Union, the agency said in a statement.

SutroVax bags $22M Series A to develop vaccines for infectious diseases

SutroVax, the vaccine spinoff from Fierce 15 honoree Sutro Biopharma that is developing vaccines for infectious diseases, announced Thursday the completion of a $22 million Series A financing.

NIAID scientists one step closer to 'universal' flu vaccine

A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.

Health officials detail need for $2B vaccines fund

In an effort to bridge the financial gap between early stage drug discovery work and late stage development, health officials this week called for the formation of a $2 billion fund to aid vaccine research against deadly diseases such as Ebola, MERS and West Nile virus. 

Pfizer talks up 'comprehensive' vaccines business

Though it can boast its ownership of the world's bestselling vaccine in Prevnar, Pfizer is not stopping there. On Tuesday, the New York City-based pharma unveiled details of its effort to build out its vaccines business by researching a range of conditions from birth until old age.

MORE NEWS